Will ClariPi's ClariAdipo product receive FDA 510K clearance by December 1, 2023?
14
187
Ṁ3.4KṀ270
resolved Dec 19
Resolved
NO1D
1W
1M
ALL
South Korean startup ClariPi's ClariAdipo is a system that helps to predict the risk of developing metabolic syndrome. It is a standalone S/W that analyzes DICOM CT abdomen fat image data sets. ClariPi has three AI products that have already received FDA clearance. This market resolves YES if ClariAdipo receives FDA 510K clearance by December 1, 2023.
Get Ṁ200 play money
🏅 Top traders
| # | Name | Total profit |
|---|---|---|
| 1 | Ṁ169 | |
| 2 | Ṁ7 | |
| 3 | Ṁ6 | |
| 4 | Ṁ5 | |
| 5 | Ṁ4 |
More related questions
Related questions
Will an AI-designed drug get FDA approval by the end of 2025?
33% chance
Will Epi-On CXL receive FDA approval by 2025
44% chance
Will a drug that didn't go through human clinical trials be approved by 2034?
28% chance
Will any product built using a large language model receive FDA clearance by the end of 2024?
18% chance
💊Will INS018_055 be FDA-approved by 2030?
48% chance
Will there be an FDA approved cure for Type 1 Diabetes by EOY 2032?
38% chance
Will there be an FDA approved cure for Parkinson's Disease by EOY 2032?
50% chance
Will a Small Language Model be cleared for clinical use by the FDA before the end of 2025?
18% chance